{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(9)"],"submitter":["Monelli F"],"pubmed_abstract":["This systematic review with meta-analysis aimed to assess the effect of diffuse liver diseases (DLD) on the risk of synchronous (S-) or metachronous (M-) liver metastases (LMs) in patients with solid neoplasms. Relevant databases were searched for systematic reviews and cross-sectional or cohort studies published since 1990 comparing the risk of LMs in patients with and without DLD (steatosis, viral hepatitis, cirrhosis, fibrosis) in non-liver solid cancer patients. Outcomes were prevalence of S-LMs, cumulative risk of M-LMs and LM-free survival. Risk of bias (ROB) was assessed using the Newcastle-Ottawa Scale. We report the pooled relative risks (RR) for S-LMs and hazard ratios (HR) for M-LMs. Subgroup analyses included DLD, primary site and continent. Nineteen studies were included (n = "],"journal":["Cancers"],"pagination":["2246"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8124499"],"repository":["biostudies-literature"],"pubmed_title":["The Effect of Diffuse Liver Diseases on the Occurrence of Liver Metastases in Cancer Patients: A Systematic Review and Meta-Analysis."],"pmcid":["PMC8124499"],"pubmed_authors":["Bassi MC","Besutti G","Ligabue G","Djuric O","Pinto C","Damato A","Monelli F","Giorgi Rossi P","Bonfatti S","Bonvicini L","Bonelli C","Fari R","Pattacini P"],"additional_accession":[]},"is_claimable":false,"name":"The Effect of Diffuse Liver Diseases on the Occurrence of Liver Metastases in Cancer Patients: A Systematic Review and Meta-Analysis.","description":"This systematic review with meta-analysis aimed to assess the effect of diffuse liver diseases (DLD) on the risk of synchronous (S-) or metachronous (M-) liver metastases (LMs) in patients with solid neoplasms. Relevant databases were searched for systematic reviews and cross-sectional or cohort studies published since 1990 comparing the risk of LMs in patients with and without DLD (steatosis, viral hepatitis, cirrhosis, fibrosis) in non-liver solid cancer patients. Outcomes were prevalence of S-LMs, cumulative risk of M-LMs and LM-free survival. Risk of bias (ROB) was assessed using the Newcastle-Ottawa Scale. We report the pooled relative risks (RR) for S-LMs and hazard ratios (HR) for M-LMs. Subgroup analyses included DLD, primary site and continent. Nineteen studies were included (n = ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2025-05-29T21:42:36.11Z","creation":"2025-05-29T21:42:36.11Z"},"accession":"S-EPMC8124499","cross_references":{"pubmed":["34067076"],"doi":["10.3390/cancers13092246"]}}